[On-Demand] Prescription Biosimilars

Tuesday, March 4, 2025, 7:00 AM - Wednesday, September 3, 2025, 11:59 PM

Discover the latest insights and strategies for managing prescription biosimilar therapies. This course will explore the key benefits and tackle the challenges of biosimilar adoption. Gain knowledge in therapeutic areas where biosimilars are transforming care. This course is intended exclusively for UC learners, with Continuing Education (CE) credits, Certificate of Completion, and/or ABIM Maintenance of Certification (MOC) points available at no cost.

Topics include:

• Biosimilar coverage across payers

• Interchangeability

• Safety and efficacy

• Value-based care

• Clinical experience

Don’t miss this opportunity to expand your knowledge and fulfill your certification requirements. Register now. This course is available at no cost to UC learners and requires a valid UC-affiliated email address for free registration.

The on-demand course* includes recorded video and resources.

*This is an on-demand activity with no specific time or location designated for participation. The learners determine whether and when to complete the activity. The content can be assessed at any point during the lifespan of the activity and there is no specific time designated for participation.

Release Date: 03/04/2025
Termination Date: 09/03/2025

Course Fees

• Free: UC Learner Only*

• $50: Non-UC Learner

* This course is intended for UC learners. During registration, you will be asked to provide your UC-affiliated email address for verification. Registrations submitted without this information or those that fail validation will be charged $50.00 registration fee on their account.

Registration Instruction

This course offers two participation tracks based on credit eligibility. Both tracks cover the same content, but the ABIM MOC Track includes an assessment requirement for MOC points. Please click the one of the tracks below to register.

• Continuing Education (CE) Credit & ABIM MOC Track: Physicians who are ABIM board-certified can earn both ABIM MOC points and AMA PRA Category 1 Credits™ by successfully completing the required assessment at the end of the course.

• Continuing Education (CE) Credit Only Track: Participants who do not need ABIM MOC points, including non-physicians and physicians not certified by ABIM, will receive AMA PRA Category 1 Credits™ only.

1. Identify the range of FDA-approved prescription biosimilars available for treating chronic conditions.
2. Explain the regulatory approval process and clinical evidence supporting prescription biosimilars efficacy and safety.
3. Demonstrate the ability to integrate prescription biosimilars into patient treatment plans, considering individual patient needs and preferences.
4. Assess the impact of prescription biosimilar adoption on healthcare costs and patient outcomes, with a focus on the California patient population.
5. Develop strategies to address operational and clinical barriers to prescription biosimilar adoption within healthcare settings.
6. Critically evaluate the effectiveness of implemented strategies in improving prescription biosimilar utilization and reducing health disparities.

The David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AMA PRA Category 1 Credits™ (1.50 hours), ABIM MOC Part 2 (1.50 hours)

Mitigation of Relevant Financial Relationships

The Accreditation Council for Continuing Medical Education (ACCME), Standards for Integrity and Independence mandates that the accreditation manages all identified relevant financial relationship(s) before the program and adequately discloses relationships to learners. The David Geffen School of Medicine at UCLA adheres to the ACCME Standards for Integrity and Independence in accredited continuing education.

The individuals below have been identified as having a position to influence the content of this educational activity. As such, they have disclosed the absence or presence of a relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships for these individuals have been mitigated.